Possibility and prospects of using bamlanivimab in patients with COVID-19
- Авторлар: Mirzaev K.B1, Sychev D.A1
-
Мекемелер:
- Russian Medical Academy of Continuous Professional Education
- Шығарылым: Том 28, № 1 (2021)
- Беттер: 17-19
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313052
- DOI: https://doi.org/10.18565/pharmateca.2021.1.17-19
- ID: 313052
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Currently, there is insufficient scientific evidence to recommend the routine use of bamlanivimab for the treatment of outpatients with COVID-19. An interim analysis of the phase II randomized placebo-controlled BLAZE-1 trial demonstrates the potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19, and its effectiveness in preventing the development of COVID-19 among medical personnel and residents of nursing homes.
Негізгі сөздер
Толық мәтін
Авторлар туралы
K. Mirzaev
Russian Medical Academy of Continuous Professional Education
D. Sychev
Russian Medical Academy of Continuous Professional Education
Әдебиет тізімі
- FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. Published November 9, 2020. (date of access: 22.12. 2020). URL: https://www.fda.gov/mvdia/143603/download
- Chen P, Nirula A., Heller B., et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N EnglJ Med. Published on-line October 28, 2020. Doi: W.W56/NEJMoa202984-9.
- National Institutes of Health (NIH) News Release. Statement - NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. Published October 26, 2020. (date of access: 22.12.2020). URL: https://www.niaid.nih.gov/news-events/ statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study.
- URL: https://www.covid19treatmentgu'idelines. nih.gov/statement-on-bamlanivimab-eua
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (date of access: 28.12.2020). URL: https://www.idsociety.org/practice-guideline/ covid-19-guideline-treatment-and-management
Қосымша файлдар
